On February 10, 2022 SystImmune, Inc. a clinical-stage company developing innovative cancer therapeutics, including novel bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs), reported the appointment of Martin Sebastian Olivo, M.D. as Chief Medical Officer, effective on February 7, 2022 (Press release, SystImmune, FEB 10, 2022, View Source [SID1234607999]). Dr. Olivo joined SystImmune, Inc. from Protara Therapeutics, Inc. where he served as the Chief Medical Officer and led the advancement of the early-stage clinical effort in the area of non-muscle invasive bladder cancer. Dr. Olivo brings decades of experience in oncology clinical research and global drug development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"It is our honor to welcome Dr. Olivo to our team," said Dr. Yi Zhu, the Chief Executive Officer of SystImmune, Inc. "As the leader of the clinical development arm of SystImmune, Inc. Dr. Olivo will be instrumental in advancing and expanding the global clinical impact of our pipeline. With several ongoing Phase II & Phase I trials, there is a huge opportunity for Dr. Olivo to leverage his strengths in product development among several oncology indications."

"I feel fortunate to join SystImmune, Inc. at this stage," said Dr. Olivo. "SystImmune, Inc. has the potential to play a meaningful role in the treatment of difficult to treat cancers and I’m looking forward to working with the many talented individuals to advance transformative therapies for people with cancer."

Before assuming his most recent role at Protara Therapeutics, Inc., Dr. Olivo led late-stage clinical efforts in breast cancer therapeutics development as the Vice President of Clinical Development at Gilead Sciences, Inc., (formerly Immunomedics, Inc.) from Aug 2018 to April 2021. Earlier, Dr. Olivo served as the Global Clinical lead at Daiichi Sankyo Cancer Enterprise, where he established a comprehensive clinical development plan to advance ADC therapeutics for IND filing in the US. Prior to that, Dr. Olivo served several roles with increasing responsibilities in the oncology group at Eisai Inc.

Dr. Olivo earned his M.D. from the University of Buenos Aires and his M.S. in Clinical and Pharmacological Research from Austral University in Buenos Aires. He also completed advanced training as a Clinical Oncologist at the University of Salvador. Dr. Olivo then held various academic and clinical positions at the School of Medicine at the University of Buenos Aires, Hospital "Dr. Enrique Tornú" and the National Cancer Institute of Canada Clinical Trials Group.